Loading
Loading
Research Overview
Multi-peptide blend targeting metabolic and fat-loss pathways; individual components act across GLP-1 signalling, lipolytic, and mitochondrial uncoupling mechanisms for a combined approach to adipose tissue reduction in research protocols.
Overview
Multi-peptide research blends combine compounds with complementary mechanistic profiles to investigate the potential for additive or synergistic effects on biological endpoints of interest. For regenerative and vitality research applications, relevant preclinical literature encompasses studies examining individual component peptides in tissue repair, cellular stress response, and regenerative signalling biology.
Preclinical research on regenerative peptide systems has explored mechanisms including growth factor receptor pathway activation, mitochondrial function support, extracellular matrix remodelling biology, and cellular autophagy regulation as contributors to tissue-level regenerative responses in relevant model systems.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, klow blend — has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Multi-peptide blend targeting metabolic and fat-loss pathways; individual components act across GLP-1 signalling, lipolytic, and mitochondrial uncoupling mechanisms for a combined approach to adipose tissue reduction in research protocols.
Support
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
